While OMP-18R5, having cross-reactivity with 4 other Fzd receptors (Fzd1/2/5/8), may show broad application for a wide range of cancers, the lack of specificity towards its intended target poses concerns for its off-target effects. Here, FZD1 is linked to cancer.